Page 15 - Lupin
FY18 will be challenging for Lupin: Nilesh Gupta
Interview with Lupin managing director Nilesh Gupta
 "FY18 will be challenging for Lupin: Nilesh Gupta")
Lupin's Q4 net profit nearly halves to Rs 380 cr as US sales slump 13%
Manufacturing costs and other expenses rose about 30% in the quarter
 "Lupin's Q4 net profit nearly halves to Rs 380 cr as US sales slump 13%")
USFDA makes 8 observations after inspecting Lupin's Aurangabad facility
Inspection was completed on April 26
 "USFDA makes 8 observations after inspecting Lupin's Aurangabad facility")
Lupin hits fresh 32-month low
Lupin dipped 3% to Rs 1,242, its fresh 32-month low on BSE in intra-day trade
Near-term concerns for Lupin
US regulator's observations add to US pressure
 "Near-term concerns for Lupin")
Lupin hits 32-month low; stock down 5% in two days
In past one-month, the stock declined 11.7% as compared to unchanged in Sensex.
 "Lupin hits 32-month low; stock down 5% in two days")
Lupin gets USFDA nod to sell generic hypertension drug in US
The Mumbai-based company's product is the generic version of Daiichi Sankyo Inc's Benicar tablets
Lupin hits fresh 52-week low; down 7.5% in six days
The stock hit a fresh 52-week low of Rs 1,320, down 1.3% on the BSE.
 "Lupin hits fresh 52-week low; down 7.5% in six days")
Lupin gets USFDA nod for drug
Wellbutrin tablets have sales of $755 million in the American market
 "Lupin gets USFDA nod for drug")
Patent infringement: Lupin's arm to pay damages to Bayer
An Australian court has asked Generic Health to pay A$30 million to Bayer Pharmaceuticals
Lupin expects muted growth in the US despite new launches
About 25 products to be launched next year will only partly compensate price erosion
 "Lupin expects muted growth in the US despite new launches")
Lupin expects muted growth in the US despite new launches
Nilesh Gupta, managing director for Mumbai based pharma major Lupin is trying to reset investors expectation as its mojo in the US market is set to get weaker in the near term.The company that reported Rs 12,958 crore revenue in the nine months of current financial earns about 48% from the US markets. "With one of the strongest pending pipelines in the US at its disposal, the company is well poised to address the pricing issue," said Siddhant Khandekar, analyst with ICICI Securities in its recent report. "We expect US sales to grow at 18% CAGR in FY16-19E to Rs 9642 crore," the report said.Following the $880 million acquisition of Gavis in 2015, the company has stepped-up product launches and ramped-up specialty drugs offering to protect its revenue from the US market.It owns one of the strongest ANDA (Abbreviated New Drug Application) pipeline comprising 344 filed and 137 pending approvals including 44 FTFs (First to File). This acquisition has strengthened its position in ...
Our priority is to acquire speciality drugmakers in the US: Nilesh Gupta
Interview with the managing director of Lupin
 "Our priority is to acquire speciality drugmakers in the US: Nilesh Gupta")
Lupin in fast lane with 5 launches in 15 days
New products expected to offset price erosion in the US
 "Lupin in fast lane with 5 launches in 15 days")
Pharma major Lupin launches pain relief drug in US
Shares of Lupin were trading 0.48 per cent higher at Rs 1,454.80 on the BSE
 "Pharma major Lupin launches pain relief drug in US")
Lupin arm to distribute anti-depressant drug in Japan
Kyowa Pharmaceutical has entered into an agreement with Astellas Pharma
Lupin gets USFDA nod for generic cough relief oral solution
The product is generic version of Endo Pharmaceuticals Inc's Hycodan oral solution in same strength
 "Lupin gets USFDA nod for generic cough relief oral solution")
Lupin eyes launch of 25 products in the US in FY18
It now has a portfolio of 128 generic products in the US market
Lupin Q3 profit up 21 pct, beats estimate
Helped by higher sales of its diabetes products in the United States
Lupin gets USFDA nod for generic anti-depressant tablets
Shares of Lupin were trading 1.86 per cent higher at Rs 1,489 apiece on BSE
